Local perivascular administration of basic fibroblast growth factor: Drug delivery and toxicological evaluation

Drug Metabolism and Disposition

Volumn 24, Issue 8, 1996, Pages 922-924

  Lopez, John J ^b   Edelman, Elazer R ^b   Stamler, Alon ^b   Morgan, James P ^b   Sellke, Frank W ^b   Simons, Michael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BASIC FIBROBLAST GROWTH FACTOR; MICROSPHERE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG RELEASE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HISTOLOGY; KIDNEY BIOPSY; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; FIBROBLAST GROWTH FACTOR 2; HEMODYNAMIC PROCESSES; MYOCARDIAL ISCHEMIA; SWINE;

ANIMALIA; SUS SCROFA;

EID: 0029790102     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. J. Folkman and M. Klagsbrun: Angiogenic Factors. Science 235, 442-447 (1987).
2. M. B. Sporn and A. B. Roberts: Peptide growth factors are multifunctional. Nature 332, 217-219 (1988).
3. W. Casscells, E. Speir, J. Sasse, M. Klagsbrun, P. Allen, M. Lee, B. Calvo, M. Chiba, L. Haggroth, J. Folkman, and S. E. Epstein: Isolation, characterization, and localization of heparin-binding growth factor in the heart. J. Clin. Invest. 85, 433-441 (1990).
4. A. Yanagisawa-Miwa, Y. Uchida, F. Nakamura, T. Tomaru, H. Kido, T. Kamijo, T. Sugimoto, K. Kaji, M. Utsuyama, C. Kurashima, and H. Ito: Salvage of infarct myocardium by angiogenic action of basic fibroblast growth factor. Science 257, 1401-1403 (1992).
5. A. Battler, M. Scheinowitz, A. Bor, D. Hasdai, Z. Bered, E. Di Segni, N. Varda-Bloom, D. Nass, S. Engelberg, M. Eldar, M. Belkin, and N. Savion: Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J. Am. Coll. Cardiol. 22, 2001-2006 (1993).
6. K. Harada, W. Grossman, M. Friedman, E. R. Edelman, P. Prasad, W. J. Manning, F. W. Sellke, and M. Simons: Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J. Clin. Invest. 94, 623-630 (1994).
7. E. Unger, S. Banai, M. Shou, D. Lazarous, M. Jaklitsch, M. Scheinowitz, R. Correa, C. Klingbeil, and S. E. Epstein: Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am. J. Physiol. 266, H1588-H1595 (1994).
8. D. F. Lazarous, M. Scheinowitz, M. Shou, E. Hodge, M. A. Rajanayagam, S. Hunsberger, W. G. Robison, Jr., J. A. Stiber, R. Correa, S. E. Epstein, and E. F. Unger: Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 91, 145-153 (1995).
9. R. Baffour, J. Berman, J. L. Garb, S. W. Rhee, J. Kaufman, and P. Friedman: Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose response effect of basic fibroblast growth factor. J. Vasc. Surg. 16, 181-191 (1992).
10. P. Cuevas, F. Carceller, S. Ortega, M. Zazo, I. Nieto, and G. Gimenez-Gallego: Hypotensive activity of fibroblast growth factor. Science 250, 1208-1210 (1991).
11. G. Mazue, F. Bertolero, L. Garofano, M. Brughera, and P. Carminati: Experience with the preclinical assessment of basic fibroblast growth factor (bFGF). Toxicol. Lett. 64/65, 329-338 (1992).
12. G. Mazue, F. Bertolo, C. Jacob, P. Sarmientos, and R. Roncucci: Preclinical and clinical studies with recombinant human basic fibroblast growth factor. Ann. N.Y. Acad. Sci. 638, 329-340 (1991).
13. E. R. Edelman, M. A. Nugent, and M. J. Karnovsky: Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. U.S.A. 90, 1513-1517 (1993).
14. E. R. Edelman, E. Mathiowitz, R. Langer, and M. Klagsbrun: Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12, 619-626 (1991).
15. H. Hondermarck, J. Courty, B. Boilly, and D. Thomas: Distribution of intravenously administered acidic and basic fibroblast growth factors in the mouse. Experientia 46, 973-974 (1990).
16. G. F. Whalen, Y. Shing, and J. Folkman: The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1, 157-164 (1989).
17. E. R. Edelman, M. A. Nugent, L. T. Smith, and M. J. Karnovsky: Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J. Clin. Invest. 89, 465-473 (1992).
18. I. Vlodavsky, J. Folkman, R. Sullivan, R. Fridman, R. Ishai-Michaeli, J. Sasse, and M. Klagsbrun: Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. U.S.A. 84, 2292-2296 (1987).
19. J. Folkman, M. Klagsbrun, J. Sasse, M. Wadzinski, D. Ingber, and I. Vlodavsky: A heparin-binding angiogenic protein-basic fibroblast growth factor is stored within basement membrane. Am. J. Pathol. 130, 393-400 (1988).
20. M. Klagsbrun: Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin. Cancer. Biol. 3, 81-87 (1992).